泰恩康：子公司收到甲巯咪唑片药品注册证书

Core Viewpoint - The announcement highlights significant regulatory approvals for two pharmaceutical products from the company's subsidiaries, indicating progress in their product development pipeline and potential market expansion [1] Group 1: Regulatory Approvals - The company's wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., received a drug registration certificate for Methimazole tablets from the National Medical Products Administration [1] - Another subsidiary, Anhui Tianenkang Pharmaceutical Co., Ltd., received an acceptance notice for the domestic production drug registration application for Indobufen tablets from the National Medical Products Administration [1]